Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

[Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists].

Jouzeau JY, Moulin D, Koufany M, Sebillaud S, Bianchi A, Netter P.

J Soc Biol. 2008;202(4):289-312. doi: 10.1051/jbio:2008034. Epub 2008 Dec 19. Review. French.

PMID:
19094928
2.

Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.

Moulin D, Bianchi A, Boyault S, Sebillaud S, Koufany M, Francois M, Netter P, Jouzeau JY, Terlain B.

Arthritis Rheum. 2005 Mar;52(3):759-69.

4.
5.

Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review.

Grygiel-Górniak B.

Nutr J. 2014 Feb 14;13:17. doi: 10.1186/1475-2891-13-17. Review.

6.

Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.

Touyz RM, Schiffrin EL.

Vascul Pharmacol. 2006 Jul;45(1):19-28. Epub 2006 Jun 16. Review.

PMID:
16782410
7.

PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.

Wilding JP.

Diabetes Obes Metab. 2012 Nov;14(11):973-82. doi: 10.1111/j.1463-1326.2012.01601.x. Epub 2012 Apr 23. Review.

PMID:
22443197
8.

Identification of plant extracts with potential antidiabetic properties: effect on human peroxisome proliferator-activated receptor (PPAR), adipocyte differentiation and insulin-stimulated glucose uptake.

Christensen KB, Minet A, Svenstrup H, Grevsen K, Zhang H, Schrader E, Rimbach G, Wein S, Wolffram S, Kristiansen K, Christensen LP.

Phytother Res. 2009 Sep;23(9):1316-25. doi: 10.1002/ptr.2782.

PMID:
19172665
9.

Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.

Koufany M, Moulin D, Bianchi A, Muresan M, Sebillaud S, Netter P, Weryha G, Jouzeau JY.

Arthritis Res Ther. 2008;10(1):R6. doi: 10.1186/ar2354. Epub 2008 Jan 16.

10.

Safety issues and prospects for future generations of PPAR modulators.

Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B.

Biochim Biophys Acta. 2007 Aug;1771(8):1065-81. Epub 2007 Feb 24. Review.

PMID:
17428730
11.

Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels.

Chopra B, Georgopoulos NT, Nicholl A, Hinley J, Oleksiewicz MB, Southgate J.

Cell Prolif. 2009 Oct;42(5):688-700. doi: 10.1111/j.1365-2184.2009.00628.x. Epub 2009 Jul 10.

PMID:
19614673
12.

Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2.

Rodríguez-Calvo R, Serrano L, Coll T, Moullan N, Sánchez RM, Merlos M, Palomer X, Laguna JC, Michalik L, Wahli W, Vázquez-Carrera M.

Diabetes. 2008 Aug;57(8):2149-57. doi: 10.2337/db08-0176. Epub 2008 Apr 28.

13.

PPAR dual agonists: are they opening Pandora's Box?

Balakumar P, Rose M, Ganti SS, Krishan P, Singh M.

Pharmacol Res. 2007 Aug;56(2):91-8. Epub 2007 Mar 14. Review.

PMID:
17428674
14.

Fenofibrate vs pioglitazone: Comparative study of the anti-arthritic potencies of PPAR-alpha and PPAR-gamma agonists in rat adjuvant-induced arthritis.

Koufany M, Jouzeau JY, Moulin D.

Biomed Mater Eng. 2014;24(1 Suppl):81-8. doi: 10.3233/BME-140977.

PMID:
24928921
15.

PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.

Gross B, Staels B.

Best Pract Res Clin Endocrinol Metab. 2007 Dec;21(4):687-710. Review.

PMID:
18054742
16.

The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.

Mansour M.

Prog Mol Biol Transl Sci. 2014;121:217-66. doi: 10.1016/B978-0-12-800101-1.00007-7. Review.

PMID:
24373239
17.

Evolution of peroxisome proliferator-activated receptor agonists.

Chang F, Jaber LA, Berlie HD, O'Connell MB.

Ann Pharmacother. 2007 Jun;41(6):973-83. Epub 2007 May 22. Review.

PMID:
17519293
18.

Atherosclerosis and cardiovascular risk reduction with PPAR agonists.

Kuusisto J, Andrulionyte L, Laakso M.

Curr Atheroscler Rep. 2007 Oct;9(4):274-80. Review.

PMID:
18173954
19.

[PPAR receptors: recent data].

Vidal H.

Ann Endocrinol (Paris). 2005 Apr;66(2 Pt 2):1S5-9. Review. French.

PMID:
15959399
20.

Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease.

Robinson E, Grieve DJ.

Pharmacol Ther. 2009 Jun;122(3):246-63. doi: 10.1016/j.pharmthera.2009.03.003. Epub 2009 Mar 24. Review.

PMID:
19318113

Supplemental Content

Support Center